The American Association for Cancer Research Project GENIE (Genomics Evidence Neoplasia Information Exchange), initiates a five-year, $36 million research collaborative with nine biopharmaceutical companies in a quest to obtain clinical and genomic data from an estimated 50,000 deidentified patients. These patients are getting treated at participating institutions. The goal: advance precision oncology and drive improved clinical decision making through an open and transparent data sharing model.
The Participating Biopharmaceutical Companies
- Bayer Healthcare Pharmaceuticals
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Genentech (Roche)
- Janssen Research & Development, LLC
A Sophisticated Cancer Registry
AACR’s Project GENIE is a publicly accessible international cancer registry of real-world data assembled through data sharing agreements between 19 cancer centers around the world. The GENIE cancer registry is supported by vendors including Sage Bionetworks and cBioPortal, to help aggregate, harmonize and link clinical-grade, next generation cancer genomic sequencing data with clinical outcomes obtained during routine medical practice from cancer patients treated at these institutions.
Accelerating GENIE’s Current Attributes
Presently the Project GENIE registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients. The data are linked to a limited set of clinical data such as age, sex, primary diagnosis, and type of tumor sample analyzed (primary or metastatic). This new collaboration will greatly expand the scope and accelerate the speed of clinical data collection.
Additional Data Coming
The new collaboration will be a catalyst to add more vital data to ultimately contribute to a richer and deeper analytical capability. For example, in the first two years, the team will add prior cancer treatments, tumor pathology and clinical outcomes to the clinical data already linked with the genomic profiles of nearly 8,000 bladder, breast, colorectal, lung, pancreatic and prostate cancer patients treated at three of the institutions participating in AACR Project GENIE including:
- Dana-Farber Cancer Institute
- Memorial Sloan Kettering Cancer Center
- Vanderbilt-Ingram Cancer Center
Year 3 to 5 Data Expansion
As the effort progresses into years three through five the plan includes an expansion of data collection to as many cancer types as possible from all participating institutions.
Project GENIE Participants
Project GENIE has been made possible by the AACR and major research centers. TrialSite News includes the list of founding institutions and new participants here.
The cBioPortal for Cancer Genomics was originally developed at Memorial Sloan Kettering Cancer Center (MSK). The public cBioPortal site is hosted by the Center for Molecular Oncology at MSK. The cBioPortal is now available under an open source license via GitHub. The software is now developed and maintained by a multi-institutional team, consisting of MSK, the Dana Farber Cancer Institute, Princess Margaret Cancer Centre in Toronto, Children’s Hospital in Philadelphia, The Hyve in the Netherlands and Bilkent University in Ankara, Turkey.
Sage Bionetworks is a nonprofit organization in Seattle that promotes open science and patient engagement in the research process. It is led by Lara Mangravite and co-founded by Stephen Friend and Eric Schadt. It was founded in 2009 as a spinout of Merck who released software, hardware, intellectual property, and staff connected to its Rosetta Inpharmatics unit. A donation from Quintiles (IQVIA) provided early funding.
AACR Project GENIE Contact
Shawn M. Sweeney, director AACR Project GENIE Coordinating Center
American Association for Cancer Research (AACR)
AACR is the world’s oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research. With more than 42,000 members, AACR operates in over 120 countries. They were founded in 1907 by 11 physicians and scientists.
Call to Action: Interested in learning more? Contact AACR’s Project GENIE.Source: American Association for Cancer Research